Evidence mapPaperPMID 34006116Full record

ArticleJournal of the American Heart Association2021

Inequities in Hypertension Control in the United States Exposed and Exacerbated by COVID-19 and the Role of Home Blood Pressure and Virtual Health Care During and After the COVID-19 Pandemic.

Adam P Bress, Jordana B Cohen, David Edmund Anstey, Molly B Conroy, Keith C Ferdinand, Valy Fontil, Karen L Margolis, Paul Muntner, Morgan M Millar, Kolawole S Okuyemi and 7 more

Open access · goldAbstract readNews
In one paragraph

Article in Journal of the American Heart Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. From Co-Design to Quality Improvement: Using the Double Diamond Framework to Develop Primary Care Redesign Priorities for Hypertension Care.Health expectations : an international journal of public participation in health care and health policy · 2026
    Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Indications for renal denervation in the treatment of hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2024
    Review
  13. Article
  14. Review
  15. Article
  16. Modifiable risk factors of inequalities in hypertension: analysis of 100 million health checkups recipients.Hypertension research : official journal of the Japanese Society of Hypertension · 2024
    Article
  17. Preventable Premature Deaths from the Five Leading Causes of Death in Nonmetropolitan and Metropolitan Counties, United States, 2010-2022.Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 1 country.

Adam P BressDepartment of Population Health Sciences Division of Health System Innovation and Research University of Utah School of Medicine Salt Lake City UT.
Jordana B CohenDepartment of Medicine Renal-Electrolyte and Hypertension Division Perelman School of Medicine at the University of Pennsylvania Philadelphia PA.
David Edmund AnsteyDivision of Cardiology Department of Medicine Columbia University Medical Center New York NY.
Molly B ConroyDivision of General Internal Medicine, Department of Internal Medicine University of Utah School of Medicine Salt Lake City UT.
Keith C FerdinandTulane University School of Medicine New Orleans LA.
Valy FontilDivision of General Internal Medicine Department of Medicine Zuckerberg San Francisco General HospitalUniversity of California San Francisco CA.
Karen L MargolisHealthPartners Institute Minneapolis MN.
Paul MuntnerDepartment of Epidemiology School of Public Health University of Alabama at Birmingham Birmingham AL.
Morgan M MillarDivision of General Internal Medicine, Department of Internal Medicine University of Utah School of Medicine Salt Lake City UT.
Kolawole S OkuyemiDepartment of Family & Preventive Medicine University of Utah School of Medicine Salt Lake City UT.
Michael K RakotzAmerican Medical Association Chicago IL.
Kristi ReynoldsDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA Pasadena CA.
Monika M SaffordDepartment of Medicine Joan and Sanford I Weill Medical College of Cornell University New York NY.
Daichi ShimboDivision of Cardiology Department of Medicine Columbia University Medical Center New York NY.
John StuligrossUtah Department of Health Salt Lake City UT.
Beverly B GreenKaiser Permanente Washington Health Research Institute Seattle WA.
April F MohantyDivision of General Internal Medicine, Department of Internal Medicine University of Utah School of Medicine Salt Lake City UT.
University of Utah · USColumbia University Irving Medical Center · USAlabama Department of Public Health · USAmerican Medical Association · USCornell University · USHealthPartners · USKaiser Permanente · USKaiser Permanente Washington Health Research Institute · USSan Francisco General Hospital · USTulane University · USUniversity of Pennsylvania · USUtah Department of Health · US

Funding

Race/ethnic differences in guideline recommended hypertension medications in VHAIK2HX002609 · VA · VA SALT LAKE CITY HEALTHCARE SYSTEM · PI April F Mohanty · 2023 to 2023
HSRD VA IK2 HX002609NCATS NIH HHS UL1 TR002538NHLBI NIH HHS K01 HL133468NHLBI NIH HHS K23 HL133843
6 · The paper itself

Abstract

The COVID-19 pandemic is a public health crisis, having killed more than 514 000 US adults as of March 2, 2021. COVID-19 mitigation strategies have unintended consequences on managing chronic conditions such as hypertension, a leading cause of cardiovascular disease and health disparities in the United States. During the first wave of the pandemic in the United States, the combination of observed racial/ethnic inequities in COVID-19 deaths and social unrest reinvigorated a national conversation about systemic racism in health care and society. The 4th Annual University of Utah Translational Hypertension Symposium gathered frontline clinicians, researchers, and leaders from diverse backgrounds to discuss the intersection of these 2 critical social and public health phenomena and to highlight preexisting disparities in hypertension treatment and control exacerbated by COVID-19. The discussion underscored environmental and socioeconomic factors that are deeply embedded in US health care and research that impact inequities in hypertension. Structural racism plays a central role at both the health system and individual levels. At the same time, virtual healthcare platforms are being accelerated into widespread use by COVID-19, which may widen the divide in healthcare access across levels of wealth, geography, and education. Blood pressure control rates are declining, especially among communities of color and those without health insurance or access to health care. Hypertension awareness, therapeutic lifestyle changes, and evidence-based pharmacotherapy are essential. There is a need to improve the implementation of community-based interventions and blood pressure self-monitoring, which can help build patient trust and increase healthcare engagement.

Indexed as

Blood Pressure Monitoring, AmbulatoryHealth Services AccessibilityHypertensionCOVID-19Healthcare DisparitiesHealth Status DisparitiesHumansNeeds AssessmentRacismSARS-CoV-2Social Determinants of HealthSocioeconomic FactorsUnited StatesCOVID‐19health disparitieshealth policyhypertension

Identifiers

PMID34006116
PMCPMC8483507
OpenAlexW3162947962

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.